As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...

“According to the writer, obesity seems to be a matter of lack—a lack of bariatric surgeries and a lack of Ozempic courtesy ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

"Ozempic Santa" Elon Musk revealed he's been using a type 2 diabetes medication to lose weight: "Technically, Mounjaro, but that doesn’t have the same ring to it." ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...